Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 11;8:16016. doi: 10.1038/ncomms16016

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017, The Author(s)

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) The mRNA levels of SRSF1 in human coronary artery smooth muscle cells (HCASMCs) treated with Ang II at 6, 12 and 24 h; n=8 each. (b) SRSF1 levels in HCASMCs treated as in a; n=9 each. (c) SRSF1 expression in cultured HCASMCs infected with Ad-GFP or Ad-SRSF1-GFP; n=5 each. (d) Δ133p53 expression in cultured HCASMCs infected with Ad-GFP or Ad-Δ133p53; n=5 each. (e) Δ133p53 levels in HCAECs infected with Ad-GFP or Ad-SRSF1; n=6 each. (f) Representative images and averaged data from wound-healing assays in HCASMCs infected with Ad-GFP, Ad-SRSF1 or Ad-Δ133p53 and treated with Ang II; n=9 each. Scale bar, 200 μm. (g,h) PCNA expression in cultured HCAECs infected with Ad-SRSF1 (g) or Ad-Δ133p53 (h); n=5 each. (i) MTT assays of HCASMCs infected with Ad-GFP, Ad-SRSF1 or Ad-Δ133p53 (m.o.i. 100, 48 h) after Ang II for 4 days; n=12 each. (j) KLF5, p21 and PCNA levels in HCASMCs infected with Δ133p53 siRNAs in the presence or absence of Ad-SRSF1 overexpression; n=7 each. (k) Δ133p53 levels in HCASMCs infected with Δ133p53 siRNAs (Δ133 si1 and Δ133 si2); n=7 each. (l) MTT assays showing the SRSF1-mediated enhancement of proliferation was inhibited by Δ133p53 knockdown in HCASMCs; n=15 each. (m) Averaged data from wound-healing assays in HCASMCs infected with Δ133p53 siRNAs with or without Ad-SRSF1 overexpression and treated with Ang II; n=5 each. (n) Schematic outline of SRSF1 -D133p53 -KLF5 axis in VSMC. Ang II, angiotensin II; SRSF1, serine/arginine-rich splicing factor 1; EGR1, early-growth-response gene 1; KLF5, Krüppel-like factor 5; VSMC, vascular smooth muscle cell. Scr indicates scrambled siRNA control. All adenoviral infection above is 100 m.o.i. for 48 h. Concentration of Ang II is 200 nM. Scr indicates scrambled siRNA control. *P<0.05, **P<0.01, one-way ANOVA (a,b,e–m). Data are mean±s.e.m. of four independent experiments (a,b,e–m).